Dr. Joshua Siner joined the Department of Medicine in the Division of Hematology as an Instructor in July of 2024. He is interested in the genomics and environmental factors that alter platelet development, function and interaction with the body to cause bleeding and thrombotic disorders. Prior to medical training, he studied the structural and functional evolutionary changes of clotting factor VIII and clotting factor IX in the laboratory of Dr. Valder Arruda. They described and detailed unexpected regulatory control of factor VIII that is unique to humans (PMID: 27734034, PMID: 23372167) and a previously undescribed factor IX variant (Padua) with increased activity (PMID: 25568350). They were the first to show the use of these variants could be used for hemophilia gene therapy without altering the safety profile or causing immune responses.
During his fellowship at Barnes-Jewish Hospital and Washington University School of Medicine, Joshua began working in the laboratory under the mentorship of Dr. Jorge Di Paola and primarily studied how changes in systemic factors, such as autoimmune disease and aging, can affect megakaryopoiesis and platelet function leading to both bleeding and thrombosis. The myeloproliferative neoplasms (MPNs) utilize the same inflammatory signaling and drives both symptoms and disease. Within MPNs, Joshua studied how signaling through megakaryocytes changes the evolution of different disease clones and affects on bleeding and clotting. His key interests are bleeding disorders (Hemophilia, von Willebrand Disease), platelet disorders, Thrombosis and Myeloproliferative neoplasms and his research interests are megakaryopoiesis and platelet disorders, Immunothrombosis and myeloproliferative neoplasms.